Impact of Armodafinil on Cognition in Multiple Sclerosis

Bruce, Jared M.; Hancock, Laura M.; Roberg, Brandon L; Brown, Amberly; Henkelman, Erik; Lynch, Sharon G.

doi:10.1097/wnn.0b013e31826df7fd

Cited by 13 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Статистически значимый эффект в отношении когнитивных функций не был обнаружен и в ранних РКИ с использованием амантадина [92,93]. Противоречивые данные получены в отношении амфетамина и его производных [94,95]; модафинила [96] и армодафинила [97]; метилфенидата [98]. Статистически значимое улучшение скорости обработки информации у пациентов с РС и КН (n = 120) показано в одном РКИ для далфампридина [99].…”

Section: медикаментозная терапия когнитивных нарушенийunclassified

Cognitive impairment and its treatment in patients with multiple sclerosis

Zabirova

Bakulin

Poydasheva

et al. 2023

Almanac of Clinical Medicine

View full text Add to dashboard Cite

Cognitive impairment (CI) is a relatively common manifestation of multiple sclerosis (MS), which can occur with any type of the disease course and activity. The largest CI prevalence and severity are observed in progressive MS. In relapsing-remitting MS the most prominent deterioration of cognitive functions is seen during relapses; however, in some patients it can continue also throughout remission. In a small number of patients CI can be the most significant symptom of the disease; in addition, it sometimes can be the only clinical feature of the relapse. Despite this, in clinical practice CI remains out of the focus of attention, and is not evaluated when assessing the disease severity and/or activity, while CI is not included into EDSS. Nonetheless, a number of specialized neuropsychological tests and batteries has been developed recently, which can be used for both screening and detailed assessment of CI in MS, as well as for assessment of its changes over time. CI has a negative impact on MS patients' quality of life, their social interactions, daily and occupational activities. The influence of disease-modifying agents on CI has been poorly investigated; however, there is evidence that they can reduce the degree of CI. The optimal choice of pathogenetic treatment in patients with CI remains understudied. There is no convincing evidence of the effectiveness of symptomatic pharmacological treatment of CI in MS, and cognitive rehabilitation is the only approach with confirmed effectiveness. Considering the limitations of this technique (its availability, quite a big number of sessions), there is a need to search for other methods to increase its efficacy, including non-invasive neuromodulation (in particular, transcranial direct current stimulation or transcranial magnetic stimulation). This article is focused on a brief review of the main diagnostic methods of CI in MS, its pathogenetic and symptomatic treatment, and cognitive rehabilitation techniques, as well as on the results of the studies on non-invasive neuromodulation.

show abstract

Section: медикаментозная терапия когнитивных нарушенийunclassified

Cognitive impairment and its treatment in patients with multiple sclerosis

Zabirova

Bakulin

Poydasheva

et al. 2023

Almanac of Clinical Medicine

View full text Add to dashboard Cite

show abstract

“…Cognitive improvement in verbal learning in our cohort may not only be a consequence of reduction of intermittent hypoxia through OSA treatment, but also through the significant reduction in fatigue alone seen in the treatment arm compared to the control arm. Reduction of fatigue using stimulant medication, armodafinil, has previously been shown to improve verbal recall as well as delayed verbal recall in people with MS (Bruce et al, 2012). The potassium channel antagonist, fampridine, which improves conduction of action potentials in demyelinated axons and is commonly used in MS may also improve both fatigue and alertness in parallel with cognitive benefits in both psychomotor speed and verbal fluency (Broicher et al, 2018).…”

Section: Casementioning

confidence: 99%

Impact of obstructive sleep apnoea on cognitive function in multiple sclerosis: A longitudinal study

McNicholas

Russell

Nolan

et al. 2020

Journal of Sleep Research

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a chronic disease of the central nervous system characterised by inflammation and neurodegeneration. MS is the most common disabling, non-traumatic, neurological condition affecting young adults, and results in a range of neurological signs and symptoms, including motor, sensory, balance and visual dysfunction, as well as cognitive impairment, fatigue and mood disorders (Compston & Coles, 2008). Cognitive impairment (CI) affects a large proportion (40%-70%) of people with MS (Chiaravalloti & DeLuca, 2008), with a resultant negative impact on performance in everyday activities, including employment status, social interactions, treatment adherence and functional independence (Amato, Zipoli, & Portaccio, 2008). CI contributes more to withdrawal from work and unemployment than physical disability in MS (Honan et al., 2012). Patterns of CI in MS typically affect information processing speed, memory (episodic, working and semantic) and executive function (Langdon et al., 2012). Fatigue is also a common disabling symptom in people with MS, which adversely

show abstract